REATA PHARMACEUTICALS INC - CL A (RETA)

Historical Holders from Q2 2016 to Q4 2023

Type / Class: Equity / CL A
Symbol: RETA

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Institutional Holders of REATA PHARMACEUTICALS INC - CL A (RETA) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (% of par)	Investors
2023 Q4	0	$0	-$2,981,708				0
2023 Q3	17,300	$2,981,708	-$3,198,726,480	$0	$0	17,235.65%	2
2023 Q2	31,493,925	$3,210,703,884	+$331,269,481	$62,915,230	$66,925,730	10,196%	211
2023 Q1	28,396,770	$2,582,227,654	-$75,945,501	$87,727,668	$163,589,120	9,092%	202
2022 Q4	29,980,270	$1,138,926,248	+$111,838,910	$27,455,373	$19,914,064	3,799%	165
2022 Q3	28,102,345	$706,207,647	-$6,113,397	$17,815,000	$31,354,000	2,513%	147
2022 Q2	27,631,574	$839,810,221	+$23,519,626	$5,905,000	$11,023,000	3,039.02%	133
2022 Q1	26,963,661	$883,834,810	+$16,924,688	$64,105,000	$17,668,000	3,276.04%	141
2021 Q4	26,709,939	$704,321,572	-$124,191,199	$12,194,000	$17,714,000	2,637%	143
2021 Q3	26,688,004	$2,685,200,348	-$18,352,591	$85,272,000	$34,178,000	10,061%	177
2021 Q2	26,542,070	$3,756,173,307	+$207,831,585	$47,343,000	$22,488,000	14,152.93%	188
2021 Q1	25,253,462	$2,520,488,719	+$25,689,266	$37,657,000	$26,383,000	9,970%	198
2020 Q4	24,685,905	$3,051,928,179	+$312,101,188	$42,340,000	$16,454,000	12,362%	193
2020 Q3	22,169,198	$2,159,297,534	-$198,458,474	$25,583,000	$36,552,000	9,741.98%	181
2020 Q2	23,190,263	$3,622,845,015	+$93,584,154	$48,959,000	$65,078,000	15,601.95%	207
2020 Q1	22,488,662	$3,246,552,389	+$17,443,037	$51,180,000	$119,641,000	14,433.98%	210
2019 Q4	22,328,924	$4,565,328,716	+$828,204,827	$35,569,000	$150,032,000	20,442.94%	215
2019 Q3	18,219,983	$1,463,018,265	+$45,314,802	$35,159,000	$18,267,000	8,028.95%	163
2019 Q2	17,639,008	$1,663,338,785	+$145,080,716	$28,135,000	$12,360,000	9,435%	156
2019 Q1	16,368,786	$1,399,187,578	+$42,581,384	$8,641,000	$12,111,000	8,547%	155
2018 Q4	15,947,499	$894,554,113	+$8,402,296	$3,719,000	$3,108,000	5,609.92%	131
2018 Q3	15,714,340	$1,284,826,970	+$296,295,233	$6,475,000	$9,304,000	8,175.83%	119
2018 Q2	12,214,064	$427,112,324	+$36,655,592	$1,014,000	$1,898,000	3,496.93%	93
2018 Q1	11,466,013	$235,163,235	+$3,997,088	$258,000	$379,000	2,051%	86
2017 Q4	11,193,182	$316,693,904	+$7,878,399	$0	$258,000	2,832%	88
2017 Q3	7,727,518	$240,322,086	+$114,069,942	$376,000		3,110%	80
2017 Q2	4,066,874	$128,667,792	-$65,567,868			3,163.87%	57
2017 Q1	6,172,788	$139,798,021	+$17,309,807			2,264.96%	54
2016 Q4	5,748,021	$125,472,003	+$3,908,026			2,182.71%	52
2016 Q3	5,554,103	$146,403,374	+$4,898,855			2,635.98%	43
2016 Q2	5,378,939	$106,232,525	+$106,232,525			1,974.97%	41